Opendata, web and dolomites

CURE SIGNED

Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CURE project word cloud

Explore the words cloud of the CURE project. It provides you a very rough idea of what is the project "CURE" about.

reinstating    grossly    despite    deviations    never    feasible    hospitalisations    dysbiotic    candidates    western    airways    huge    inflammatory    initiation    tuned    characteristically    persistence    presentation    microbiome    interactions    phages    abundance    pandemic    deaths    acute    eubiosis    health    interface    bacteriophages    untangling    expression    populations    airway    clinical    infect    vitro    suboptimal    unexplored    adding    predictive    innovation    infections    atopic    interventions    asthma    humans    appearing    symptom    naturally    preparations    host    reaching    immune    generally    therapy    efforts    strategy    cure    reveal    microbe    bacterial    burden    follow    close    allergy    countries    asthmatic    predict    imposes    model    calls    infection    unacceptably    patients    indicate    data    tool    imbalanced    treatments    viruses    virus    rebalancing    appropriate    world    disease    relatively    notwithstanding    upper    dysbiosis    phage    ecology    mixtures    pathophysiology    susceptibility    disruptive    respiratory    attacks    dysregulation    levels    fine    treatment    validated   

Project "CURE" data sheet

The following table provides information about the project.

Coordinator
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON 

Organization address
address: 6 CHRISTOU LADA STR
city: ATHINA
postcode: 10561
website: www.elke.uoa.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Project website https://www.cureasthma.eu
 Total cost 2˙971˙750 €
 EC max contribution 2˙971˙750 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-1-2016-2017
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) coordinator 353˙750.00
2    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 1˙128˙000.00
3    SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS CH (DAVOS PLATZ) participant 287˙500.00
4    UNIVERSYTET MEDYCZNY W LODZI. PL (LODZ) participant 232˙500.00
5    GIORGI ELIAVA INSTITUTE OF BACTERIOPHAGY, MICROBIOLOGY AND VIROLOGY GE (TBILISI) participant 222˙500.00
6    IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON EL (ATHINA) participant 222˙500.00
7    UMEA UNIVERSITET SE (UMEA) participant 217˙500.00
8    MARIOS LYMARAKIS KAI SIA EE EL (GERAKAS ATTIKI) participant 135˙000.00
9    EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING BE (Brussels) participant 112˙500.00
10    ELIAVA BIO PREPARATIONS LTD GE (TBILISI) participant 60˙000.00

Map

 Project objective

The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans. We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma

 Deliverables

List of deliverables.
Website and logo Websites, patent fillings, videos etc. 2019-05-31 10:20:03
Variability in space & time Documents, reports 2019-05-31 10:20:01
Data Management Plan Documents, reports 2019-05-31 10:20:04

Take a look to the deliverables list in detail:  detailed list of CURE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Evangelos Andreakos, Ivan Zanoni, Ioanna E Galani
Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control
published pages: 67-75, ISSN: 0952-7915, DOI: 10.1016/j.coi.2018.10.007
Current Opinion in Immunology 56 2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

PANACHE (2020)

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.

Read More  

NOVIRUSES2BRAIN (2019)

''One size fits all'' unique drug to eradicate multiple viral species simultaneously from the central nervous system of co-infected individuals

Read More  

SHERO (2019)

Self-HEaling soft RObotics

Read More